Obesity Management

1. Clinical Overview

Summary

Obesity is a chronic, relapsing, neurohormonal disease characterised by excessive adipose tissue accumulation (Body Mass Index ≥30 kg/m²) that poses significant health risks. It represents one of the greatest public health challenges of the 21st century, with prevalence rates tripling globally since 1975. Obesity is not simply a lifestyle choice or lack of willpower—it is a complex pathophysiological condition involving dysregulation of hypothalamic appetite control circuits, peripheral hormonal signaling (leptin, ghrelin, GLP-1, PYY), genetic predisposition, environmental factors, and psychosocial determinants. [1,2]

The disease drives the development of life-limiting cardiometabolic complications including Type 2 Diabetes Mellitus (T2DM), hypertension, dyslipidaemia, obstructive sleep apnoea (OSA), non-alcoholic fatty liver disease (NAFLD/MASH), polycystic ovary syndrome (PCOS), osteoarthritis, and multiple malignancies. Management requires a chronic disease model with tiered, multidisciplinary interventions ranging from lifestyle modification (Tier 1-2) through pharmacotherapy with novel incretin-based agents (Tier 3) to metabolic/bariatric surgery (Tier 4). [3,4]

Recent therapeutic advances—particularly once-weekly GLP-1 receptor agonists (semaglutide 2.4mg, liraglutide 3.0mg) and dual GLP-1/GIP co-agonists (tirzepatide)—have revolutionised medical management, achieving weight loss magnitudes (15-22.5%) previously only attainable through surgical intervention. Bariatric surgery remains the most effective long-term treatment, producing sustained weight loss, T2DM remission in > 60% of cases, and significant reductions in cardiovascular mortality. [5,6,7]

Exam Detail: Pathophysiological Paradigm Shift: Modern understanding recognises obesity as a disorder of the biological "set point" for body weight regulation, controlled by the hypothalamic melanocortin system. Weight loss triggers powerful counter-regulatory responses (increased hunger via AgRP/NPY neurons, reduced metabolic rate, enhanced nutrient absorption efficiency) that defend the elevated set point. This explains the extremely high rates of weight regain following lifestyle interventions alone (80-95% at 5 years) and underscores the need for chronic pharmacological or surgical treatment. [8]

Weight Stigma and Clinical Care: Weight bias among healthcare professionals is well-documented and adversely affects patient engagement, treatment adherence, and clinical outcomes. The 2020 Joint International Consensus Statement called for ending the stigmatisation of obesity and recognising it as a chronic disease requiring compassionate, evidence-based management rather than moralising or blame. [2]

Key Facts

• Definition: BMI ≥30 kg/m² (WHO criteria). Lower thresholds apply for Asian populations: ≥27.5 kg/m² (obese), ≥23 kg/m² (overweight) due to increased metabolic risk at lower BMI.
• Waist Circumference: Superior predictor of visceral adiposity and cardiometabolic risk compared to BMI alone. High risk: Men > 102cm (40"), Women > 88cm (35"). For Asians: Men > 90cm, Women > 80cm.
• Prevalence (UK): ~28% adults obese, ~36% overweight (Health Survey for England 2021). Childhood obesity: 10% reception (age 4-5), 21% Year 6 (age 10-11).
• Comorbidity Burden: Obesity accounts for 70-80% of T2DM burden, 30-40% of hypertension, and significantly increases risk of > 13 cancer types.
• GLP-1 Receptor Agonists: Semaglutide 2.4mg (Wegovy): ~15% weight loss; Tirzepatide 15mg (Mounjaro): ~22.5% weight loss (STEP 1 and SURMOUNT-1 trials). [5,6]
• Bariatric Surgery: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy produce 25-35% total body weight loss and 60-80% excess weight loss. T2DM remission rates: 60-80%. [7]
• Mortality: Obesity reduces life expectancy by 8-10 years (BMI > 40). Bariatric surgery associated with 29% reduction in long-term mortality (SOS study, 20-year follow-up). [9]

Clinical Pearls

Obesity is a Disease, Not a Choice: Recognise obesity as a chronic neurohormonal disease with strong genetic determinants (heritability 40-70%). The biological "set point" for body weight is actively defended by hypothalamic circuits. Weight regain after loss is not a moral failure—it is a predictable physiological response to negative energy balance. Treatment requires long-term, often lifelong intervention.

The "Obesity Paradox": In certain chronic diseases (heart failure, chronic kidney disease, dialysis), higher BMI is paradoxically associated with better survival ("reverse epidemiology"). Proposed mechanisms include nutritional reserve, earlier disease recognition, protective effects of adipokines, and confounding by illness severity. This does NOT mean obesity is protective—it likely reflects survivor bias and loss of lean mass in cachexic states.

Pharmacological Weight Loss Requires Ongoing Treatment: GLP-1 agonists are highly effective while administered but weight regain occurs upon cessation (STEP 1 extension data: ~67% weight regain within 1 year of stopping). Obesity is a chronic disease requiring chronic treatment—just as we do not stop antihypertensives when BP normalises, we should not discontinue anti-obesity medications when weight targets are achieved.

"Metabolic Surgery" Concept: Bariatric surgery works through multiple mechanisms beyond gastric restriction: altered gut hormone secretion (increased GLP-1, PYY; decreased ghrelin), changes in bile acid metabolism, gut microbiome restructuring, and altered nutrient sensing. The term "metabolic surgery" reflects these pleiotropic metabolic effects independent of weight loss. [10]

Secondary Causes are Rare (less than 10%): While it is important to screen for hypothyroidism, Cushing's syndrome, and medication-induced weight gain, these account for less than 10% of obesity cases and rarely cause isolated severe obesity. Most obesity is primary/polygenic. Do not delay evidence-based management while pursuing extensive endocrine workup in the absence of clinical features.

Weight Loss Targets: Even modest weight loss (5-10% body weight) produces clinically significant improvements in glycaemic control, blood pressure, lipids, and liver fat. Do not let "perfect" (achieving ideal BMI) be the enemy of "good" (meaningful health improvements). [11]

---

2. Epidemiology

Global Burden

Obesity has reached pandemic proportions, with profound public health and economic consequences:

Socioeconomic Gradient: In high-income countries, obesity prevalence is inversely associated with socioeconomic status (SES). In low-income countries, the reverse is often true (obesity associated with affluence). [1]

Childhood Obesity: Worldwide, 38 million children less than 5 years were overweight in 2019. Children with obesity are at high risk of adult obesity (70-80% track into adulthood) and early onset of cardiometabolic disease. [12]

Comorbidity Profile: The "5 Ms"

Obesity is a major driver of non-communicable disease burden:

BMI and Mortality (J-Shaped Curve): Mortality risk is lowest at BMI 22-25, increases progressively with BMI > 30, and also increases at very low BMI (less than 18.5, reflecting malnutrition or underlying illness). Each 5 kg/m² increase in BMI above 25 is associated with ~30% increase in all-cause mortality. [13]

Economic Burden

Obesity imposes enormous direct healthcare costs (treatment of obesity and related diseases) and indirect costs (lost productivity, absenteeism, disability). In the UK, obesity-related NHS costs are estimated at £6.1 billion annually, projected to reach £9.7 billion by 2050 if trends continue. [3]

---

3. Aetiology and Pathophysiology

Regulation of Energy Balance: The Hypothalamic-Adipose Axis

Energy homeostasis is regulated by a complex neuroendocrine system centered in the hypothalamic arcuate nucleus (ARC):

Exam Detail: Key Neuronal Populations in the Arcuate Nucleus:

1. Orexigenic (Hunger-Promoting) Neurons: Express Neuropeptide Y (NPY) and Agouti-Related Peptide (AgRP). Activation increases food intake and decreases energy expenditure. Stimulated by:

   • Ghrelin (secreted by gastric fundus during fasting)
   • Low leptin levels (fasting/weight loss state)

2. Anorexigenic (Satiety-Promoting) Neurons: Express Pro-opiomelanocortin (POMC) and Cocaine- and Amphetamine-Regulated Transcript (CART). POMC is cleaved to α-MSH, which activates melanocortin-4 receptors (MC4R) to reduce appetite. Stimulated by:

   • Leptin (secreted by adipocytes in proportion to fat mass)
   • Insulin (secreted by pancreatic β-cells)
   • GLP-1 and PYY (secreted by intestinal L-cells postprandially)

Second-Order Neurons: ARC neurons project to the paraventricular nucleus (PVN), lateral hypothalamus (LH), and ventromedial hypothalamus (VMH) to integrate signals and modulate feeding behaviour, sympathetic output, and thyroid/reproductive axes. [14]

Molecular Pathophysiology of Obesity

1. Leptin Resistance

• Leptin is a 16-kDa adipokine secreted by white adipocytes in proportion to fat mass. It signals energy sufficiency to the hypothalamus, inhibiting NPY/AgRP and activating POMC/CART neurons.
• Leptin Resistance: In obesity, chronically elevated leptin levels desensitise hypothalamic leptin receptors (ObRb). Mechanisms include:
  • Suppressor of Cytokine Signaling-3 (SOCS-3) upregulation
  • Endoplasmic reticulum (ER) stress in hypothalamic neurons
  • Impaired leptin transport across the blood-brain barrier
• Consequence: The brain interprets the obese state as a state of starvation despite abundant energy stores, failing to suppress appetite or increase energy expenditure. [8]

2. Ghrelin Dysregulation

• Ghrelin is the "hunger hormone" secreted by gastric P/D1 cells. Levels rise preprandially and fall postprandially.
• In obesity, fasting ghrelin levels are paradoxically lower, but postprandial suppression is blunted, leading to persistent hunger.
• Bariatric Surgery Effect: Sleeve gastrectomy removes the ghrelin-secreting gastric fundus, leading to marked reductions in ghrelin and appetite. [15]

3. Incretin Deficiency/Resistance

• GLP-1 (Glucagon-Like Peptide-1) is secreted by intestinal L-cells in response to nutrient ingestion. It:
  • Delays gastric emptying
  • Enhances glucose-dependent insulin secretion
  • Acts on hypothalamic GLP-1 receptors to promote satiety
• In obesity, GLP-1 secretion may be reduced and central GLP-1 receptor sensitivity impaired.
• Therapeutic Rationale: Pharmacological GLP-1 agonists (semaglutide, liraglutide) bypass these defects, producing dose-dependent weight loss. [5]

4. Adiposopathy ("Sick Fat Disease")

Adipose tissue in obesity undergoes pathological remodeling:

• Adipocyte Hypertrophy: Enlarged adipocytes become hypoxic, trigger inflammatory signaling, and undergo apoptosis.
• Macrophage Infiltration: M1 (pro-inflammatory) macrophages infiltrate adipose tissue, releasing TNF-α, IL-6, IL-1β, and MCP-1.
• Adipokine Dysregulation:
  • Decreased adiponectin (anti-inflammatory, insulin-sensitising)
  • Increased leptin, resistin, RBP-4 (pro-inflammatory, insulin resistance-promoting)
• Ectopic Fat Deposition: Impaired adipocyte expandability leads to lipid "spillover" into liver (NAFLD), muscle (myosteatosis), pancreas (β-cell dysfunction), and pericardium (pericardial fat → arrhythmias). [16]

5. Gut Microbiome Alterations

Obesity is associated with reduced microbial diversity, increased Firmicutes:Bacteroidetes ratio, and enhanced capacity for energy harvest from dietary fiber. Gut dysbiosis may contribute to:

• Increased short-chain fatty acid (SCFA) production and colonic energy extraction
• Endotoxemia (lipopolysaccharide translocation) → systemic inflammation
• Altered bile acid metabolism → impaired FXR/TGR5 signaling [17]

Genetic Factors

• Monogenic Obesity (less than 5%): Rare mutations in leptin (LEP), leptin receptor (LEPR), POMC, MC4R, PCSK1. Present with early-onset severe obesity and hyperphagia. MC4R mutations are the most common monogenic cause (~2-5% of severe obesity).
• Syndromic Obesity: Prader-Willi syndrome (15q11-13 deletion, hyperphagia, intellectual disability), Bardet-Biedl syndrome, Alström syndrome.
• Polygenic Obesity (> 90%): > 1000 genetic loci identified by GWAS, each with small effect size. FTO gene variants are most strongly associated (1-3 kg difference in body weight). Heritability of BMI: 40-70%. [18]

Environmental and Behavioural Factors

• Obesogenic Environment: Abundance of energy-dense, hyperpalatable foods; large portion sizes; ubiquitous food marketing; sedentary work/leisure; urban design discouraging physical activity.
• Sleep Deprivation: Disrupts leptin/ghrelin balance (↓leptin, ↑ghrelin), increases cortisol, impairs glucose metabolism.
• Chronic Stress: Hypothalamic-pituitary-adrenal (HPA) axis activation → cortisol hypersecretion → visceral fat accumulation.
• Obesogenic Medications: Atypical antipsychotics (olanzapine, clozapine), tricyclic antidepressants, mood stabilisers (valproate, lithium), antidiabetic agents (sulfonylureas, thiazolidinediones, insulin), corticosteroids, beta-blockers (older agents), antihistamines. [19]

---

4. Clinical Presentation

History Taking

Comprehensive Weight History:

• Onset and Trajectory: Age of onset, highest/lowest adult weight, weight fluctuations, triggers for weight gain (pregnancy, medication, life events).
• Previous Weight Loss Attempts: Diets tried, amount lost, duration of maintenance, reasons for regain.
• Dietary Assessment: 24-hour recall, eating patterns (regular meals vs grazing), binge eating, night eating syndrome, emotional eating. Use validated tools (e.g., SCOFF questionnaire for eating disorders).
• Physical Activity: Occupational activity, structured exercise (type, frequency, duration), barriers to activity (joint pain, breathlessness).
• Sleep: Hours per night, sleep quality, snoring, witnessed apnoeas, daytime somnolence (STOP-Bang score for OSA screening).

Review of Systems (Screening for Complications):

• Cardiovascular: Dyspnoea, orthopnoea, ankle swelling, chest pain.
• Metabolic: Polyuria, polydipsia (T2DM), fatigue, cold intolerance (hypothyroidism).
• Respiratory: Snoring, apnoeas, daytime sleepiness (OSA).
• Gastrointestinal: Reflux, dyspepsia, right upper quadrant discomfort (NAFLD).
• Musculoskeletal: Joint pain (knees, hips, back), reduced mobility.
• Reproductive: Menstrual irregularity, hirsutism, infertility (PCOS).
• Psychological: Mood, anxiety, binge eating, body image distress, weight stigma experiences.

Secondary Causes (Screen):

• Endocrine: Hypothyroidism, Cushing's syndrome, hypothalamic disorders (craniopharyngioma, post-surgical/radiation), growth hormone deficiency, hypogonadism, insulinoma (rare).
• Medications: Detailed drug history (see Obesogenic Medications above).
• Genetic/Syndromic: Childhood-onset severe obesity, developmental delay, dysmorphic features, family history.

Psychosocial Assessment:

• Motivation and Readiness for Change: Use stages of change model (precontemplation, contemplation, preparation, action, maintenance).
• Barriers: Financial constraints, lack of social support, mental health comorbidities, cultural/religious dietary practices.
• Weight Stigma: Experiences of discrimination, impact on healthcare engagement.

Red Flags (Urgent Investigation Required)

⚠️ Red Flag: - Rapid Unexplained Weight Gain: Consider hypothyroidism, Cushing's syndrome, heart failure, hypothalamic lesion, medication-induced.

• Features of Cushing's Syndrome: Moon facies, dorsocervical fat pad ("buffalo hump"), purple striae, proximal myopathy, easy bruising, hypertension, hyperglycaemia.
• Headaches with Visual Disturbance: Idiopathic intracranial hypertension (IIH, pseudotumor cerebri)—especially in women of reproductive age with severe obesity. Papilloedema on fundoscopy. Can cause permanent vision loss.
• Severe OSA with Cardiorespiratory Compromise: Oxygen desaturation, CO₂ retention, pulmonary hypertension, cor pulmonale.
• Obesity Hypoventilation Syndrome (Pickwickian Syndrome): Daytime hypercapnia (PaCO₂ > 45 mmHg), hypoxia, somnolence in absence of other causes of hypoventilation. Associated with very high BMI (usually > 40).
• Signs of Eating Disorder: Binge eating, purging, severe dietary restriction, preoccupation with weight/shape, electrolyte disturbances.

---

5. Clinical Examination

Anthropometric Measurements

Body Mass Index (BMI):

• Calculation: Weight (kg) / [Height (m)]²
• Classification (WHO, for populations of European descent):

• Asian Populations (WHO, revised): Obesity ≥27.5, Overweight ≥23, due to higher metabolic risk at lower BMI.

Waist Circumference (WC):

• Measurement: Midpoint between iliac crest and lowest rib, end of expiration, patient standing.
• High Risk Thresholds (European): Men > 102cm (40"), Women > 88cm (35")
• Asian Populations: Men > 90cm, Women > 80cm
• Superior Predictor: WC correlates better with visceral adipose tissue (VAT) and cardiometabolic risk than BMI. Independent risk factor for T2DM, CVD, mortality.

Waist-to-Hip Ratio (WHR):

• Central vs Peripheral Adiposity: WHR > 0.90 (men) or > 0.85 (women) indicates central (visceral) obesity.
• "Apple" vs "Pear" Shape: Central obesity ("apple") confers higher metabolic risk than peripheral/gluteofemoral obesity ("pear").

General Inspection

• Body Habitus: Distribution of adiposity (central vs peripheral, gynoid vs android).
• Mobility: Observe gait, use of walking aids.
• Breathing: Tachypnoea, use of accessory muscles (OSA, obesity hypoventilation).
• Alertness: Daytime somnolence (OSA).

Cardiovascular System

• Blood Pressure: Use appropriately sized cuff (cuff bladder should encircle ≥80% of arm circumference). Standard cuff underestimates BP in obese individuals. Look for hypertension (often present).
• Heart Sounds: Distant heart sounds (adipose tissue), signs of heart failure (elevated JVP, S3 gallop, pulmonary crackles).
• Peripheral Oedema: Venous insufficiency, lymphoedema, cardiac failure.
• Peripheral Pulses: Assess for peripheral arterial disease.

Signs of Comorbidities and Complications

Endocrine/Metabolic:

• Acanthosis Nigricans: Velvety, hyperpigmented, thickened skin in intertriginous areas (neck, axillae, groin). Marker of insulin resistance. Associated with T2DM, PCOS, rarely GI malignancy.
• Skin Tags (Acrochordons): Multiple benign skin tags, especially neck—associated with insulin resistance.
• Hirsutism: Ferriman-Gallwey score ≥8. Suggests PCOS or hyperandrogenism.
• Striae: Pink/purple striae (active) vs white/silver (old). Wide (> 1cm), purple striae → consider Cushing's.
• Proximal Myopathy: Difficulty rising from squatting position (Cushing's, hypothyroidism).

Hepatic:

• Hepatomegaly: Palpable liver edge (NAFLD). Usually non-tender unless acute steatohepatitis.

Respiratory:

• Reduced Chest Expansion: Restrictive defect from adipose tissue.
• Cyanosis: Severe OSA, obesity hypoventilation.

Musculoskeletal:

• Joint Examination: Crepitus, effusion, reduced range of motion in knees, hips (osteoarthritis).
• Spinal Tenderness: Degenerative disc disease.

Neurological:

• Papilloedema: Fundoscopy for idiopathic intracranial hypertension (especially in young women with headaches).
• Carpal Tunnel Syndrome: Thenar wasting, positive Tinel's/Phalen's signs.

Dermatological:

• Intertrigo: Erythematous, macerated rash in skin folds (moisture, friction, secondary Candida infection).
• Stasis Dermatitis: Venous insufficiency (lower legs).

---

6. Investigations

Initial Screening Panel (All Patients)

Metabolic Screening:

• HbA1c: Screen for T2DM (≥48 mmol/mol) and prediabetes (42-47 mmol/mol). Preferred over fasting glucose (reflects glycaemic control over 3 months).
• Fasting Lipid Profile: Total cholesterol, LDL, HDL, triglycerides. Typical pattern: ↑TG, ↓HDL, small dense LDL (atherogenic dyslipidaemia).
• Liver Function Tests: ALT, AST, GGT, ALP, bilirubin, albumin. ↑ALT/AST suggests NAFLD. Calculate AST:ALT ratio (> 1 suggests fibrosis/cirrhosis).
• Thyroid Function: TSH (screen for hypothyroidism). Free T4 if TSH abnormal.
• Renal Function: Urea, creatinine, eGFR. Urinalysis for proteinuria (obesity-related glomerulopathy, diabetic nephropathy).

Additional Tests:

• Full Blood Count: Exclude anaemia, polycythaemia (OSA-related hypoxia).
• Uric Acid: Hyperuricaemia (gout risk).
• Vitamin D: 25-OH Vitamin D (often deficient in obesity).

Non-Invasive Liver Fibrosis Assessment (if NAFLD)

• FIB-4 Score: Uses age, AST, ALT, platelet count. less than 1.3 = low risk, 1.3-2.67 = intermediate, > 2.67 = high risk of advanced fibrosis.
• NAFLD Fibrosis Score: Uses age, BMI, diabetes, AST, ALT, platelets, albumin.
• Transient Elastography (FibroScan): Non-invasive measurement of liver stiffness (kPa). > 8 kPa suggests significant fibrosis, > 12.5 kPa cirrhosis. Also measures CAP (Controlled Attenuation Parameter) for steatosis quantification.

Secondary Cause Workup (if Clinically Indicated)

Only perform if clinical features suggest secondary cause:

Obstructive Sleep Apnoea Screening

• STOP-Bang Questionnaire: Score ≥3 = high risk for OSA.
  • Snoring
  • Tiredness
  • Observed apnoeas
  • Pressure (hypertension)
  • BMI > 35
  • Age > 50
  • Neck circumference > 40cm (men), > 37cm (women)
  • Gender (male)
• Epworth Sleepiness Scale: Score > 10 = excessive daytime sleepiness.
• Sleep Study (if high risk): Home oximetry, limited channel study, or polysomnography. Apnoea-Hypopnoea Index (AHI): less than 5 normal, 5-15 mild, 15-30 moderate, > 30 severe OSA.

Cardiovascular Risk Assessment

• QRISK3 or Framingham Score: 10-year CVD risk. Obesity increases risk, but calculators may underestimate in very obese individuals.
• ECG: Screen for LVH, arrhythmias (atrial fibrillation more common in obesity).
• Echocardiography (if indicated): LV function, diastolic dysfunction, pulmonary hypertension (if severe OSA).

Pre-Bariatric Surgery Workup

• Upper GI Endoscopy: Exclude peptic ulcer, hiatus hernia, Barrett's oesophagus.
• Abdominal Ultrasound: Gallstones, hepatic steatosis.
• Nutritional Assessment: Vitamin B12, folate, iron studies, calcium, 25-OH Vitamin D (optimise pre-op).
• Psychological Assessment: Screen for eating disorders, severe depression, unrealistic expectations, substance abuse. Contraindications include active substance abuse, untreated severe mental illness, inability to adhere to lifelong follow-up.
• Pregnancy Test: Women of childbearing age (avoid pregnancy immediately post-surgery).

---

7. Management

Obesity management requires a chronic disease model with lifelong intervention. Treatment is individualised, multidisciplinary, and tiered based on BMI and comorbidity burden.

Management Algorithm

                INITIAL ASSESSMENT
                BMI + Waist Circumference
           Comorbidity Screening (T2DM/HTN/OSA)
                        ↓
        ┌───────────────┼───────────────┐
        │               │               │
    BMI 25-29.9     BMI 30-34.9     BMI ≥35 or 30-34.9 + comorbidity
   (Overweight)     (Obesity I)      (Obesity II-III)
        ↓               ↓               ↓
     TIER 1-2         TIER 2          TIER 3
    (Lifestyle)     (Lifestyle)    (Lifestyle + Pharmacotherapy)
        │            ↓ 3-6 mo             ↓
        │         Inadequate          Consider Tier 4 if:
        │         response?           - BMI ≥40, OR
        │            ↓ YES             - BMI 35-39.9 + comorbidity, OR
        │         TIER 3              - BMI 30-34.9 + recent T2DM (rapid pathway)
        │      (Pharmacotherapy)               ↓
        │            ↓                  TIER 4 (Bariatric Surgery)
        └────────→ CHRONIC DISEASE MODEL ←─────┘
                   Lifelong follow-up
              Monitor comorbidities, relapse

---

Tier 1: Public Health and Primary Prevention

Population-Level Interventions:

• Taxation on sugar-sweetened beverages
• Food industry reformulation (reducing sugar/salt content)
• Restrictions on marketing of unhealthy foods to children
• Urban planning (active transport, green spaces)
• School-based interventions (healthy meals, physical activity)

Not covered further here (focus on clinical management).

---

Tier 2: Lifestyle Modification (Foundation of All Treatment)

All patients require dietary, physical activity, and behavioural interventions—regardless of whether pharmacotherapy or surgery is used.

Dietary Interventions

Energy Deficit is Fundamental:

• Weight loss requires sustained negative energy balance (intake < expenditure).
• Target Deficit: 500-600 kcal/day → ~0.5 kg/week loss (~2 kg/month). More aggressive deficits may be used in specialist settings.

Dietary Approaches (No Single "Best" Diet): Adherence and sustainability matter more than macronutrient composition. Choose diet that suits patient preference and cultural context.

Behavioural Strategies:

• Self-monitoring (food diary, apps, weighing)
• Goal setting (SMART goals: Specific, Measurable, Achievable, Relevant, Time-bound)
• Stimulus control (remove trigger foods, plan shopping, meal prep)
• Cognitive restructuring (address unhelpful thoughts about food/weight)
• Relapse prevention (identify high-risk situations, develop coping strategies)
• Group support (commercial programmes: Slimming World, Weight Watchers; peer support groups)

Physical Activity

Recommendations:

• Minimum (Weight Maintenance): 150 minutes/week moderate-intensity (brisk walking, cycling) OR 75 minutes/week vigorous-intensity (running, swimming).
• Weight Loss: Often requires 200-300 minutes/week moderate-intensity.
• Resistance Training: 2-3 sessions/week to preserve lean mass during weight loss.

Benefits Beyond Weight Loss:

• Improved cardiorespiratory fitness (independent predictor of mortality)
• Improved insulin sensitivity
• Preservation of lean mass
• Mood improvement
• Reduced visceral fat (even without total weight loss)

Barriers in Obesity:

• Joint pain (low-impact options: swimming, cycling, water aerobics)
• Breathlessness (start very gradually, increase incrementally)
• Stigma/embarrassment (home-based exercise, specialised gyms)
• Physical limitations (consider referral to physiotherapist, exercise specialist)

Behavioural Support

• Intensity Matters: More frequent contact (weekly or fortnightly sessions) more effective than infrequent or one-off consultations.
• Delivery Modes: Individual, group, digital (apps, online programmes), or hybrid.
• Duration: Minimum 3 months intensive phase. Long-term (1-2 year) programmes more effective for sustained weight loss.

Expected Outcomes (Lifestyle Alone)

• Modest Weight Loss: Mean 3-5 kg at 12 months in routine clinical practice.
• High Regain Rates: 80-95% regain most/all weight within 5 years due to biological adaptations (metabolic adaptation, hormonal changes favouring weight regain).
• Clinical Value: Even 5-10% weight loss produces meaningful health improvements (HbA1c reduction, BP reduction, lipid improvement). Do not dismiss "modest" weight loss as failure.

---

Tier 3: Pharmacotherapy

Indications (NICE CG189):

• BMI ≥30 kg/m², OR
• BMI 27-29.9 kg/m² with weight-related comorbidity (T2DM, hypertension, dyslipidaemia, OSA, NAFLD)
• AND inadequate response to lifestyle intervention alone (usually 3-6 months trial)

Principles:

• Always adjunct to lifestyle modification (not monotherapy).
• Set realistic targets: 5-10% weight loss (clinically meaningful).
• Review at 3-6 months: Continue if beneficial response (usually ≥5% weight loss). Stop if inadequate response.
• Chronic treatment for chronic disease (weight regain on cessation).

1. GLP-1 Receptor Agonists (First-Line Pharmacotherapy)

Mechanism:

• Bind GLP-1 receptors in hypothalamus (arcuate, paraventricular nuclei) → ↑satiety, ↓appetite
• Delay gastric emptying → prolonged satiation
• May improve insulin secretion (glucose-dependent, low hypoglycaemia risk)

STEP 1 Trial (Semaglutide 2.4mg): [5]

• Design: RCT, 1961 adults with BMI ≥30 (or ≥27 + comorbidity), non-diabetic. Semaglutide 2.4mg weekly vs placebo, both with lifestyle intervention.
• Results:
  • "Mean weight loss: -14.9% (semaglutide) vs -2.4% (placebo) at 68 weeks."
  • 50% achieved ≥15% weight loss (semaglutide) vs 5% (placebo).
• Adverse Events: Nausea (44%), diarrhoea (30%), vomiting (24%), mostly mild-moderate, transient. Discontinuation due to AE: 7%.

Side Effects (GLP-1 agonists):

• Common: Nausea (especially during titration), vomiting, diarrhoea, constipation, abdominal pain. Usually transient (first 4-8 weeks). Reduce by slow titration.
• Serious (Rare):
  • Acute pancreatitis (discontinue immediately if suspected)
  • Gallstones/acute cholecystitis (rapid weight loss increases risk)
  • Hypoglycaemia (rare, unless combined with sulfonylurea/insulin)
  • Suicidal ideation (post-marketing reports, causal link unclear)
  • Gastrointestinal obstruction (rare case reports)
• Contraindications: Personal/family history of medullary thyroid carcinoma or MEN2 (theoretical risk from rodent studies, no human cases), pregnancy/breastfeeding, diabetic ketoacidosis, severe gastroparesis.

NICE Guidance (TA875, 2023):

• Semaglutide 2.4mg recommended for BMI ≥35, OR BMI 30-34.9 with ≥1 weight-related comorbidity AND ≥1 psychological/physical functional impairment.
• Maximum 2-year treatment duration (stop if less than 5% weight loss at 6 months).
• Not currently funded for routine use in NHS due to cost-effectiveness concerns. Specialist initiation only.

2. Dual GLP-1/GIP Receptor Agonists

SURMOUNT-1 Trial (Tirzepatide): [6]

• Design: RCT, 2539 adults with BMI ≥30 (or ≥27 + comorbidity), non-diabetic. Tirzepatide 5/10/15mg weekly vs placebo, both with lifestyle intervention.
• Results (72 weeks):
  • "Mean weight loss: -15.0% (5mg), -19.5% (10mg), -20.9% (15mg) vs -3.1% (placebo)."
  • 50% achieved ≥20% weight loss (15mg dose).
• Mechanism: Dual agonist of GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors. GIP may have additive effects on adipose tissue metabolism and insulin sensitivity.
• Superiority to Semaglutide: Head-to-head trials in T2DM show greater weight loss with tirzepatide. Obesity-specific comparator trials ongoing.

Side Effects: Similar to GLP-1 agonists (GI side effects, pancreatitis risk, gallstones).

3. Orlistat (Xenical, Alli)

Mechanism:

• Gastric and pancreatic lipase inhibitor.
• Blocks absorption of ~30% dietary fat (excreted in faeces).

Dosing:

• 120mg three times daily with meals (or up to 1 hour after meal). Omit dose if meal skipped or fat-free.

Efficacy:

• Modest weight loss: ~3 kg additional loss vs placebo at 1 year.
• More effective if combined with low-fat diet.

Side Effects:

• Gastrointestinal (very common): Oily spotting, flatulence with discharge, faecal urgency/incontinence, steatorrhoea. Occur if patient eats high-fat meal (negative reinforcement to adhere to low-fat diet).
• Fat-Soluble Vitamin Deficiency: ↓ Vitamins A, D, E, K. Advise multivitamin supplementation (taken ≥2 hours after orlistat).
• Rare: Severe liver injury (rare case reports), oxalate nephropathy (increased colonic oxalate absorption).

Role in Practice:

• Second-line (GLP-1 agonists more effective).
• Lower cost (available over-the-counter as Alli 60mg).
• Useful if injections refused/contraindicated.

NICE Recommendation: Continue only if ≥5% weight loss at 3 months.

4. Naltrexone/Bupropion (Mysimba, Contrave)

Mechanism:

• Naltrexone: Opioid antagonist, blocks auto-inhibitory feedback on POMC neurons.
• Bupropion: Norepinephrine-dopamine reuptake inhibitor, activates POMC neurons.
• Combination enhances melanocortin signaling → ↓appetite.

Dosing:

• Start 1 tablet daily (naltrexone 8mg/bupropion 90mg), titrate over 4 weeks to 2 tablets twice daily.

Efficacy:

• Mean weight loss ~5-6% at 1 year vs placebo.

Side Effects:

• Nausea, constipation, headache, dizziness, insomnia, dry mouth.
• Contraindications: Uncontrolled hypertension, seizure disorders, eating disorders, opioid use (naltrexone antagonises opioids), MAO inhibitor use.

Role: Third-line. Moderate efficacy. Less used in UK.

5. Other Agents (Limited Use)

• Topiramate (off-label): Anticonvulsant with weight loss side effect. 5-7% weight loss. Side effects: cognitive slowing, paraesthesia, teratogenic (contraception essential). Not licensed for obesity in UK.
• Metformin (off-label): Modest weight loss (~2-3 kg) in insulin-resistant patients. Used in PCOS, prediabetes. Not a primary obesity treatment.
• SGLT2 Inhibitors (diabetes agents): Modest weight loss (~2-4 kg) via glycosuria. Not licensed for obesity.

---

Tier 4: Bariatric (Metabolic) Surgery

Indications (NICE CG189):

• Standard Criteria:
  • BMI ≥40 kg/m², OR
  • BMI 35-39.9 kg/m² with significant weight-related comorbidity (T2DM, hypertension, OSA, NAFLD) that could improve with weight loss
• Rapid Access Pathway (NICE NG28, 2022):
  • BMI ≥30 kg/m² (or ≥27.5 for Asian ethnicity) + recent-onset T2DM (diagnosed within 10 years) → consider expedited surgery for T2DM remission
• Additional Requirements:
  • All non-surgical measures tried and failed
  • Patient fit for anaesthesia and surgery
  • Commitment to lifelong follow-up and lifestyle changes

Contraindications:

• Absolute: Unstable severe mental illness, active substance abuse, inability to adhere to nutritional supplementation/follow-up.
• Relative: Pregnancy (defer until postpartum), uncontrolled eating disorder.

Surgical Procedures

EWL = Excess Weight Loss: Percentage of excess weight (above ideal body weight) lost.

Current Trends:

• Sleeve Gastrectomy has overtaken RYGB as most common procedure globally (simpler, no malabsorptive limb, lower complication rate).
• Gastric Banding is declining (lower efficacy, high reoperation rates).
• BPD/DS reserved for super-obesity (BMI > 50) due to high malabsorptive complications.

Mechanisms of Weight Loss (Beyond Restriction)

Modern concept: "Metabolic Surgery" reflects multiple mechanisms:

1. Gastric Restriction: Reduced stomach capacity → early satiety.
2. Malabsorption: Bypassed small bowel reduces nutrient absorption (RYGB, BPD/DS).
3. Gut Hormone Changes:
   • ↑ GLP-1 and PYY (satiety hormones) from rapid nutrient delivery to distal ileum
   • ↓ Ghrelin (hunger hormone) after sleeve gastrectomy (fundus removed)
4. Bile Acid Signaling: Altered bile acid metabolism → FXR/TGR5 receptor activation → improved glucose metabolism.
5. Gut Microbiome: Rapid shifts in microbial composition post-surgery.
6. Food Preferences: Reduced preference for high-fat/high-sugar foods (mechanism unclear).

Metabolic Effects (Independent of Weight Loss)

• T2DM Remission: Occurs within days to weeks post-surgery, before significant weight loss. Remission defined as HbA1c less than 48 mmol/mol off diabetes medications. Rates: 60-80% (varies by procedure, diabetes duration, baseline HbA1c). Remission more likely if T2DM duration less than 5 years. [7]
• Hypertension: Remission/improvement in 50-70%.
• Dyslipidaemia: ↑HDL, ↓TG, ↓LDL (especially post-bypass).
• OSA: Resolution/improvement in 70-80%.
• NAFLD: Significant improvement in steatosis and NASH. May reverse fibrosis.

Complications

Early (less than 30 days):

• Anastomotic Leak: 1-3% (RYGB, sleeve). Presents with tachycardia, fever, abdominal pain. Requires urgent CT, reoperation. High morbidity/mortality if delayed.
• Bleeding: Intra-abdominal or intraluminal (staple line).
• Venous Thromboembolism (VTE): PE/DVT (obesity is VTE risk factor). Prophylaxis essential.
• Wound Infection: Higher in open vs laparoscopic.

Late (> 30 days):

• Dumping Syndrome (RYGB): Rapid gastric emptying of hyperosmolar food → vasomotor symptoms (sweating, palpitations, dizziness) ± reactive hypoglycaemia (late dumping, 1-3 hours postprandial). Manage with dietary modification (small, frequent meals; avoid simple sugars).
• Internal Hernia (RYGB): Bowel herniates through mesenteric defects. Presents with intermittent abdominal pain, vomiting, obstruction. Requires high index of suspicion, CT, surgical repair.
• Marginal Ulcer (RYGB): Ulcer at gastrojejunal anastomosis. Risk factors: NSAIDs, smoking, H. pylori. Presents with abdominal pain, bleeding. Treat with PPI, H. pylori eradication, smoking cessation.
• Stricture: Narrowing at gastrojejunal anastomosis (RYGB) or mid-stomach (sleeve). Presents with dysphagia, vomiting. Treat with endoscopic dilatation.
• GERD: May worsen after sleeve gastrectomy (consider RYGB if severe pre-existing GERD).
• Gallstones: Rapid weight loss → supersaturated bile. Consider prophylactic ursodeoxycholic acid for 6 months post-op.

Nutritional Deficiencies (see table above):

• Vitamin B12 Deficiency: Loss of intrinsic factor (bypassed stomach). Requires lifelong IM or high-dose oral B12 supplementation.
• Iron Deficiency Anaemia: Bypassed duodenum (site of iron absorption). May need IV iron.
• Calcium/Vitamin D Deficiency: Secondary hyperparathyroidism, bone loss (osteoporosis risk). Requires Ca citrate (not carbonate, needs acid for absorption), high-dose Vit D.
• Thiamine (B1) Deficiency: Risk of Wernicke's encephalopathy with persistent vomiting. Prophylactic high-dose thiamine if recurrent vomiting.
• Protein Malnutrition: Especially after BPD/DS. Monitor albumin, protein intake.

Weight Regain:

• Incidence: 20-30% regain significant weight (> 25% of lost weight) by 5-10 years.
• Causes: Pouch/sleeve dilatation, inadequate behavioural change, metabolic adaptation, hormonal changes.
• Management: Reinforce lifestyle, consider revision surgery (limited efficacy), consider pharmacotherapy (GLP-1 agonists show promise).

Long-Term Outcomes

Swedish Obese Subjects (SOS) Study (landmark prospective controlled study, 20-year follow-up): [9]

• Design: 2010 patients undergoing bariatric surgery vs 2037 matched controls receiving usual care.
• Results:
  • "Sustained weight loss: -18% (surgery) vs +1% (control) at 15 years."
  • "Mortality: 29% reduction in all-cause mortality (surgery vs control). Driven by ↓CVD deaths, ↓cancer deaths."
  • "Diabetes Prevention: 78% reduction in diabetes incidence."
• Conclusion: Bariatric surgery reduces long-term mortality and prevents diabetes.

Perioperative Management

Pre-operative:

• Weight Loss: Some centres require 5-10% loss pre-op (reduce liver size, demonstrate commitment, improve surgical risk).
• Nutritional Optimisation: Correct deficiencies (Vit D, B12, iron).
• VTE Prophylaxis: LMWH, TED stockings, early mobilisation.
• Smoking Cessation: Essential (↑ulcer risk, ↓healing).
• Anaesthetic Assessment: OSA screening (consider pre-op CPAP).

Post-operative:

• Dietary Progression: Clear fluids → puréed diet (week 1-2) → soft diet (week 3-4) → normal diet (gradual).
• Protein Targets: 60-80 g/day to preserve lean mass.
• Lifelong Supplementation: Multivitamin, calcium, vitamin D, vitamin B12, iron (protocol varies by procedure).
• Follow-up:
  • Frequent early (2 weeks, 6 weeks, 3 months, 6 months, 12 months)
  • Annual thereafter (lifelong)
  • Monitor weight, nutritional status (FBC, B12, folate, iron, calcium, Vit D, PTH, albumin), comorbidities.
• Contraception: Avoid pregnancy for 12-18 months post-op (rapid weight loss, nutritional deficiencies teratogenic). Malabsorptive procedures may reduce oral contraceptive efficacy → consider LARC (Nexplanon, IUD).

---

Multidisciplinary Team (MDT) Approach

Effective obesity management requires coordinated input from:

• GP/Primary Care Physician: Initial assessment, comorbidity management, long-term monitoring.
• Endocrinologist/Obesity Physician: Specialist medical management, pharmacotherapy initiation.
• Dietitian: Individualised dietary plans, nutritional counselling, post-bariatric nutritional management.
• Physiotherapist/Exercise Specialist: Exercise prescription, mobility optimisation.
• Psychologist: CBT for eating behaviours, body image, pre-surgical psychological assessment.
• Bariatric Surgeon: Surgical assessment, operative intervention.
• Specialist Nurse: Patient education, lifestyle coaching, follow-up coordination.

---

8. Complications and Long-Term Outcomes

Weight Regain (The Biology of Relapse)

Metabolic Adaptation:

• Energy expenditure decreases beyond that predicted by loss of body mass (~200-500 kcal/day lower).
• Resting metabolic rate (RMR) suppression persists for years ("The Biggest Loser" study showed persistent metabolic slowing 6 years post-competition). [21]

Hormonal Adaptations:

• ↑ Ghrelin (hunger hormone)
• ↓ Leptin (satiety hormone)
• ↓ Peptide YY, ↓ GLP-1 (gut satiety hormones)
• ↓ Thyroid hormones (T3, adaptive thermogenesis)
• Result: Increased hunger, reduced satiety, reduced energy expenditure → powerful drive to regain weight.

Implications:

• Weight regain is NOT a personal failure—it is a predictable biological response.
• Chronic disease requires chronic treatment (ongoing pharmacotherapy, surgical intervention, lifelong behavioural support).

Obesity-Related Mortality

• Dose-Response Relationship: Each 5 kg/m² increase in BMI above 25 → ~30% increase in all-cause mortality, ~40% increase in vascular mortality. [13]
• Causes of Death: Predominantly cardiovascular (MI, stroke, heart failure), cancer, diabetes, chronic kidney disease, liver disease.
• Life Expectancy: Severe obesity (BMI 40-45) reduces life expectancy by 8-10 years.

Cardiovascular Disease

• Hypertension: RR 2-3 (obesity major driver).
• Coronary Artery Disease: RR 1.5-2.5. Mediated by hypertension, dyslipidaemia, T2DM, inflammation, prothrombotic state.
• Heart Failure: RR 2-3. Both HFrEF and HFpEF. "Obesity cardiomyopathy" (biventricular hypertrophy, diastolic dysfunction, later systolic dysfunction).
• Atrial Fibrillation: RR 1.5-2. Mediated by LA dilatation, inflammation, OSA.
• Stroke: RR 1.5-2 (ischaemic and haemorrhagic).

Type 2 Diabetes Mellitus

• Causality: Obesity accounts for 80-85% of T2DM risk in Western populations.
• Mechanism: Adiposopathy → insulin resistance → β-cell exhaustion.
• Prevention: 5-10% weight loss reduces T2DM incidence by 40-60% in high-risk individuals (Diabetes Prevention Program). [11]
• Remission: Achievable with intensive weight loss. DiRECT trial (800 kcal/day diet for 12 weeks) → 46% T2DM remission at 1 year, 36% at 2 years. [20]

Malignancy

Obesity-Associated Cancers (> 13 types): [22]

• Adenocarcinomas: Oesophagus (RR 4.8), endometrium (RR 7.1), kidney (RR 1.8), colon (RR 1.5), pancreas (RR 1.5), breast (postmenopausal, RR 1.5), liver (RR 1.8), ovary (RR 1.2), gallbladder (RR 1.6).
• Haematological: Multiple myeloma (RR 1.2).
• Other: Thyroid (RR 1.3), meningioma (RR 1.5).

Mechanisms: Insulin resistance/hyperinsulinemia (IGF-1 pathway activation), chronic inflammation, adipokine dysregulation (↓adiponectin), sex hormone alterations (aromatisation of androgens to oestrogens in adipose tissue → endometrial/breast cancer), altered gut microbiome, immune dysregulation.

Obstructive Sleep Apnoea (OSA)

• Prevalence: 40-70% of obese individuals have OSA.
• Mechanism: Upper airway fat deposition, reduced pharyngeal muscle tone, altered respiratory control.
• Consequences: Daytime somnolence, ↑HTN (resistant), ↑arrhythmias (AF), ↑CVD, ↑RTA risk, neurocognitive impairment, metabolic dysfunction (intermittent hypoxia → insulin resistance).
• Treatment: Weight loss (curative in many cases), CPAP, mandibular advancement device, positional therapy, surgery (uvulopalatopharyngoplasty) rarely used now.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASH)

• Prevalence: 70-90% of obese individuals have hepatic steatosis. 20-30% have steatohepatitis (MASH, previously NASH).
• Progression: Steatosis → MASH → Fibrosis → Cirrhosis (10-20% over 10-20 years) → Hepatocellular carcinoma.
• Diagnosis: ↑ALT/AST (often AST:ALT less than 1 until cirrhosis), imaging (ultrasound, MRI-PDFF), FibroScan (liver stiffness + CAP score).
• Treatment: Weight loss is only proven treatment (7-10% loss improves steatosis, ≥10% loss may reverse fibrosis). Semaglutide shows promise (NASH resolution in trials). Avoid hepatotoxins (alcohol, methotrexate).

Polycystic Ovary Syndrome (PCOS)

• Prevalence: 50-70% of PCOS patients are obese.
• Bidirectional Relationship: Obesity worsens insulin resistance → hyperandrogenism. Hyperandrogenism → central adiposity.
• Treatment: Weight loss (5-10%) improves ovulatory function, fertility, hirsutism, metabolic profile. Metformin, GLP-1 agonists (off-label) adjuncts.

Musculoskeletal

• Osteoarthritis: RR 4-5 (knees), 2-3 (hips). Mechanical load + metabolic inflammation ("metabolic OA"). Leading cause of disability in obesity.
• Gout: Obesity → hyperuricemia (reduced renal clearance, increased production). RR 2-3.
• Chronic Back Pain: Intervertebral disc degeneration, facet joint arthropathy.

Reproductive

• Female Infertility: Anovulation (PCOS), impaired IVF outcomes, ↑miscarriage risk.
• Pregnancy Complications: Gestational diabetes (RR 3-4), pre-eclampsia (RR 2-3), macrosomia, stillbirth, caesarean section, thromboembolic disease.
• Male Infertility: Reduced testosterone (aromatisation to oestrogen), ↓sperm quality, erectile dysfunction.

Psychological

• Depression/Anxiety: Bidirectional relationship (obesity → depression; depression → weight gain via medication, inactivity, emotional eating). RR 1.5-2.
• Eating Disorders: Binge Eating Disorder (BED) in 20-30% of treatment-seeking obese individuals. Night Eating Syndrome.
• Body Image Distress: Quality of life impairment, social isolation.
• Weight Stigma: Discrimination in employment, healthcare, education. Adversely affects mental health and treatment engagement. [2]

---

9. Prognosis and Prevention

Prognosis with Treatment

Lifestyle Intervention Alone:

• Mean weight loss: 3-5 kg at 1 year in routine clinical practice.
• Long-term maintenance: Poor (80-95% regain within 5 years).
• Clinical benefit: Even "modest" 5-10% loss improves cardiometabolic health.

Pharmacotherapy (GLP-1 Agonists):

• Mean weight loss: 10-20% while on treatment (semaglutide 15%, tirzepatide 20-22%).
• Maintenance: Requires ongoing treatment. Weight regain upon cessation (~67% regain within 1 year).
• Cardiometabolic benefits: ↓HbA1c, ↓BP, ↓TG, ↑HDL, cardiovascular risk reduction (SELECT trial: semaglutide 2.4mg reduced MACE by 20%). [23]

Bariatric Surgery:

• Mean weight loss: 20-35% total body weight. Sustained at 10+ years (though 20-30% experience significant regain).
• T2DM remission: 60-80% (higher with RYGB, lower with sleeve; duration less than 5 years predicts remission).
• Mortality reduction: 29% (SOS study, 20-year follow-up). [9]
• Quality of life: Significant improvements in physical function, mental health, social functioning.

Weight Cycling ("Yo-Yo Dieting")

• Definition: Repeated cycles of weight loss and regain.
• Prevalence: Extremely common given poor long-term maintenance of lifestyle interventions.
• Concerns: Historically debated whether weight cycling increases CVD risk, mortality. Current evidence does NOT support harm from weight cycling per se (confounded by underlying health conditions driving weight fluctuation). Weight loss attempts should NOT be discouraged due to fear of regain.

Prevention (Primary and Secondary)

Primary Prevention (Population-Level):

• Addressed in Tier 1 (public health measures). Early childhood interventions, school-based programmes, urban planning, food policy.

Secondary Prevention (High-Risk Individuals):

• Prediabetes/Metabolic Syndrome: Intensive lifestyle intervention (Diabetes Prevention Program model: 7% weight loss, 150 min/week activity) → 58% reduction in diabetes incidence. [11]
• Obesity Pharmacotherapy: Emerging evidence for use in "at-risk" BMI 27-29.9 with comorbidities to prevent progression.

Pregnancy:

• Pre-Conception Weight Loss: Improves fertility, reduces gestational diabetes/pre-eclampsia risk. Bariatric surgery improves pregnancy outcomes but defer pregnancy 12-18 months post-op.
• Gestational Weight Gain: Adherence to Institute of Medicine (IOM) guidelines reduces maternal/fetal complications. Obese women should gain less than 5-9 kg during pregnancy (vs 11-16 kg for normal BMI).

Children and Adolescents:

• Childhood obesity tracks into adulthood (70-80% persistence).
• Family-based interventions most effective.
• Pharmacotherapy (liraglutide, semaglutide) now licensed for age ≥12 years in some jurisdictions.
• Bariatric surgery reserved for severe obesity (BMI ≥35 + comorbidity) with completed/near-completed growth (Tanner stage 4-5).

---

10. Special Populations

Older Adults (≥65 years)

Considerations:

• Sarcopenic Obesity: Loss of muscle mass + obesity. High morbidity/mortality. Weight loss may worsen sarcopenia.
• Obesity Paradox: In some cohorts (heart failure, CKD, dialysis), higher BMI associated with better survival. May reflect reverse causation (cachexia in severe illness).
• Goals: Focus on functional status, quality of life, metabolic health rather than BMI alone. Preserve lean mass (resistance training, adequate protein ≥1 g/kg/day during weight loss).
• Surgery: Higher perioperative risk but benefits can still outweigh risks if carefully selected (comprehensive geriatric assessment).

Ethnic Minorities

Asian Populations:

• Higher metabolic risk at lower BMI (greater visceral adiposity, insulin resistance).
• Lower BMI thresholds: Overweight ≥23, Obese ≥27.5 (WHO), or ≥25 (some guidelines).
• Pharmacotherapy/surgery thresholds should use ethnicity-specific BMI cutoffs.

Black Populations:

• Higher lean mass, different body composition (may underestimate adiposity by BMI alone).
• Higher prevalence of hypertension, T2DM at any BMI.
• Often underrepresented in clinical trials.

Pregnancy and Postpartum

• Pre-Conception: Weight loss improves fertility, pregnancy outcomes.
• Pregnancy: NOT the time for weight loss. Gestational weight gain per IOM guidelines. Screen for gestational diabetes (OGTT 24-28 weeks). Manage OSA (CPAP safe in pregnancy).
• Postpartum: Breastfeeding promotes modest weight loss (may mobilise maternal fat stores). Lifestyle interventions safe during breastfeeding. GLP-1 agonists contraindicated (no data). Bariatric surgery typically avoided until ≥12-18 months postpartum (nutritional demands of lactation).

Post-Bariatric Surgery Pregnancy

• Defer Pregnancy 12-18 Months: Period of rapid weight loss, nutritional vulnerability (teratogenic risk).
• Contraception: Malabsorptive surgery may reduce oral contraceptive efficacy → LARC recommended.
• Nutritional Monitoring: Intensive monitoring for deficiencies (iron, B12, folate, calcium, vitamin D). Supplement aggressively.
• Outcomes: Generally improved vs pre-surgery (lower gestational diabetes, hypertension, macrosomia). Slight increase in small-for-gestational-age (nutritional restriction), internal hernia risk (anatomical changes).

---

11. Guidelines and Evidence

Major Guidelines

Landmark Trials and Studies

1. Diabetes Prevention Program (DPP): [11]

• Design: RCT, 3234 adults with prediabetes. Intensive lifestyle intervention (7% weight loss target, 150 min/week activity) vs metformin vs placebo.
• Results: 58% reduction in diabetes incidence (lifestyle) vs 31% (metformin) vs placebo at 3 years.
• Impact: Established lifestyle intervention as standard of care for diabetes prevention.

2. Look AHEAD (Action for Health in Diabetes):

• Design: RCT, 5145 adults with T2DM. Intensive lifestyle intervention vs diabetes support and education. Primary outcome: cardiovascular events.
• Results: Greater weight loss in intervention group (8.6% vs 0.7% at 1 year, sustained to 8 years). NO difference in primary cardiovascular outcome (stopped early for futility). Significant improvements in HbA1c, fitness, quality of life, medication use.
• Impact: Lifestyle intervention improves metabolic health but did not reduce CV events in established T2DM (study may have been underpowered; late intervention).

3. DiRECT (Diabetes Remission Clinical Trial): [20]

• Design: Cluster RCT, 306 adults with T2DM (duration less than 6 years, BMI 27-45). Total diet replacement (800-850 kcal/day formula diet for 12-20 weeks) + stepped food reintroduction vs usual care.
• Results: 46% T2DM remission (HbA1c less than 48 mmol/mol off medications) at 1 year (intervention) vs 4% (control). Remission rate 36% at 2 years. Remission strongly associated with weight loss (86% if lost ≥15 kg).
• Impact: Proof-of-concept that intensive dietary intervention can induce T2DM remission. Adopted into UK NHS Diabetes Remission Programme.

4. STEP 1 (Semaglutide 2.4mg for Obesity): [5]

• See Pharmacotherapy section above.
• Impact: Revolutionised medical management of obesity. Weight loss approaching surgical magnitudes.

5. SURMOUNT-1 (Tirzepatide for Obesity): [6]

• See Pharmacotherapy section above.
• Impact: Dual GLP-1/GIP agonist superiority to GLP-1 alone. Highest efficacy pharmacotherapy to date.

6. Swedish Obese Subjects (SOS) Study: [9]

• See Bariatric Surgery section above.
• Impact: First prospective controlled study demonstrating mortality reduction with bariatric surgery. Long-term (20-year) follow-up.

7. SELECT (Semaglutide and Cardiovascular Outcomes in Obesity): [23]

• Design: RCT, 17,604 adults with BMI ≥27, established CVD (no diabetes). Semaglutide 2.4mg weekly vs placebo. Primary outcome: MACE (CV death, non-fatal MI, non-fatal stroke).
• Results: 20% reduction in MACE (semaglutide vs placebo) over ~3 years. Weight loss: -9.4% (semaglutide) vs -0.9% (placebo).
• Impact: First cardiovascular outcomes trial for obesity pharmacotherapy showing benefit. Establishes semaglutide as cardiometabolic therapeutic (beyond weight loss).

---

12. Patient and Layperson Explanation

What is obesity and why does it happen?

Obesity means having too much body fat (usually measured by Body Mass Index, BMI ≥30 kg/m²). It is NOT simply a matter of eating too much or lacking willpower. Obesity is a complex medical condition involving:

• Your genes: Some people inherit a tendency to gain weight more easily.
• Your brain's "set point": Your brain has a target weight it tries to defend. When you lose weight, your brain thinks you are starving and makes you hungrier and slows down your metabolism to protect your fat stores. This is why keeping weight off is so hard.
• Your environment: Modern life makes it easy to overeat (large portions, high-calorie foods everywhere) and hard to be active (desk jobs, cars, screens).
• Your hormones: Hormones like leptin, ghrelin, and GLP-1 control hunger and fullness. In obesity, these signals get disrupted.

Why does obesity matter?

Carrying excess weight increases your risk of serious health problems:

• Type 2 Diabetes: Your body becomes resistant to insulin (the hormone that controls blood sugar).
• Heart Disease: High blood pressure, clogged arteries, heart attacks, strokes.
• Joint Problems: Extra weight damages knees, hips, and back, causing pain and difficulty walking.
• Sleep Apnoea: Your breathing stops and starts during sleep, making you tired and increasing heart strain.
• Fatty Liver: Fat builds up in your liver, potentially leading to scarring (cirrhosis).
• Cancer: Higher risk of 13 types of cancer, including bowel, breast, kidney, and womb cancers.

Good news: You do NOT need to reach an "ideal" weight to improve your health. Losing just 5-10% of your body weight (e.g., 7-10 kg if you weigh 100 kg) makes a big difference to your diabetes, blood pressure, and joint pain.

What treatments are available?

1. Lifestyle Changes (Foundation of All Treatment)

• Diet: No single "best" diet. The key is eating fewer calories than you burn. Choose an approach you can stick to (low-carb, low-fat, Mediterranean, meal replacements—pick what works for you).
• Activity: Aim for 150-300 minutes per week of moderate activity (brisk walking, swimming, cycling). Start small if you have joint pain or breathlessness.
• Behaviour: Keep a food diary, set realistic goals, get support (groups, apps, family).

Reality check: Most people lose 3-5 kg with lifestyle changes alone and regain it within 5 years. This is NOT your fault—it is biology fighting back. Many people need extra help.

2. Weight-Loss Injections (e.g., Wegovy, Saxenda)

• What they are: Weekly or daily injections that copy a natural hormone (GLP-1) that tells your brain "I'm full."
• How well they work: Average 10-20% weight loss (e.g., 10-20 kg if you weigh 100 kg). Much more effective than diet alone.
• Side effects: Nausea, diarrhoea, vomiting (usually settle after a few weeks). Rare serious risks include pancreatitis (severe tummy pain).
• Catch: You need to keep taking them. If you stop, most weight comes back (like stopping blood pressure tablets—the underlying problem is still there).
• Availability: Expensive. Currently limited NHS funding in UK. Criteria: BMI ≥30 (or ≥27.5 if Asian) with weight-related health problems.

3. Weight-Loss Surgery (Bariatric Surgery)

• What it is: Operations that make your stomach smaller or change how your gut absorbs food. Types include gastric bypass and sleeve gastrectomy.
• Who can have it: BMI ≥40, OR BMI ≥35 with serious health problems (diabetes, high blood pressure, sleep apnoea). Also considered for BMI ≥30 if you have recent diabetes (to put it into remission).
• How well it works: Best long-term treatment. Average 20-35% weight loss (e.g., 25-35 kg if you weigh 100 kg). Can cure diabetes in 60-80% of people.
• Risks: Major surgery. Early risks: leaks, bleeding, blood clots (1-3% serious complications). Long-term: vitamin deficiencies (need lifelong supplements), dumping syndrome (feeling faint after sugary foods), 20-30% regain some weight.
• Commitment: Lifelong follow-up, vitamin supplements, dietary changes.

Why is losing weight so hard?

When you lose weight, your body fights back:

• You feel hungrier (your "hunger hormone" ghrelin increases).
• You feel less full after eating (your "fullness hormones" leptin, GLP-1, PYY decrease).
• Your metabolism slows down (you burn fewer calories at rest, even years after losing weight).

This is why "eat less, move more" often fails in the long run. It is NOT a lack of willpower—it is powerful biological forces. Obesity is a chronic disease that usually needs chronic treatment (like taking tablets for high blood pressure or diabetes).

What about weight stigma?

Many people with obesity experience blame, discrimination, and judgment from others (including doctors). This is wrong. Obesity is a medical condition, not a moral failing. If you have experienced weight stigma, please still seek help—you deserve compassionate, evidence-based care.

What should I do?

1. Talk to your doctor: Get screened for complications (diabetes, blood pressure, liver, sleep apnoea).
2. Start with lifestyle changes: Even small changes help (swap sugary drinks for water, walk 10 minutes daily, eat more vegetables).
3. Consider extra help: If lifestyle alone is not enough, ask about weight-loss medications or surgery. These are proven, effective treatments.
4. Be kind to yourself: Obesity is not your fault. Weight regain after loss is normal biology, not personal failure. Keep trying—every effort benefits your health.

---

13. Examination Focus (MRCP, MRCPCH, FRACP)

High-Yield Exam Topics

1. Classification and Risk Assessment

• BMI thresholds (including Asian-specific thresholds)
• Waist circumference cutoffs
• Difference between BMI and waist circumference as risk markers (visceral fat)

2. Pathophysiology

• Hypothalamic appetite regulation (NPY/AgRP vs POMC/CART neurons)
• Leptin resistance mechanism
• Role of GLP-1 in satiety
• Adiposopathy and ectopic fat deposition

3. Secondary Causes

• Endocrine: Cushing's (clinical features, screening tests), hypothyroidism (rarely causes massive obesity), hypothalamic lesions
• Genetic: MC4R mutations (most common monogenic cause), Prader-Willi syndrome
• Medications: Atypical antipsychotics, steroids, insulin, sulfonylureas, valproate

4. Comorbidities

• "5 Ms": Metabolic, Mechanical, Mental, Malignant, Mortality
• T2DM (strongest association, 80% attributable to obesity)
• OSA (screening with STOP-Bang, management with CPAP)
• NAFLD (AST:ALT ratio, FibroScan, treatment with weight loss)
• CVD (mechanisms: HTN, dyslipidaemia, inflammation, prothrombotic state)
• Cancer (13 types, especially endometrial RR 7, oesophageal RR 4.8)

5. Pharmacotherapy

• GLP-1 agonists: Semaglutide 2.4mg (~15% loss, STEP 1), liraglutide 3.0mg (~8% loss). Mechanism (central satiety, delayed gastric emptying). Side effects (GI, pancreatitis, gallstones). Contraindication (MEN2, medullary thyroid Ca).
• Tirzepatide: Dual GLP-1/GIP agonist (~22% loss, SURMOUNT-1).
• Orlistat: Lipase inhibitor, blocks 30% fat absorption. Side effects (steatorrhoea, fat-soluble vitamin deficiency). "Educational" side effects enforce low-fat diet.
• NICE criteria for pharmacotherapy: BMI ≥30 or ≥27 + comorbidity. Continue if ≥5% loss at 3-6 months.

6. Bariatric Surgery

• NICE criteria: BMI ≥40, or ≥35 + comorbidity. Rapid access: BMI ≥30 + recent T2DM (less than 10 years).
• Procedures: RYGB (restrictive + malabsorptive, 60-70% EWL, 75-80% T2DM remission), Sleeve (restrictive + hormonal, 50-60% EWL, 60-70% T2DM remission), Band (declining use).
• Mechanisms: Beyond restriction → ↑GLP-1/PYY, ↓ghrelin, bile acid signaling, microbiome changes.
• Complications: Anastomotic leak (1-3%, EMERGENCY), dumping syndrome (RYGB, manage with dietary modification), internal hernia (intermittent pain, high index of suspicion), marginal ulcer (avoid NSAIDs), nutritional deficiencies (B12, iron, calcium, vitamin D—lifelong supplementation).
• SOS study: 29% mortality reduction at 20 years.

7. Special Scenarios

• Pregnancy: Defer bariatric surgery for 12-18 months. Malabsorptive surgery reduces oral contraceptive efficacy → LARC. Gestational weight gain per IOM guidelines.
• Older adults: Sarcopenic obesity, obesity paradox (in HF, CKD). Focus on functional status.
• Asian populations: Lower BMI thresholds (≥27.5 obese, ≥23 overweight).

Common MCQ/SBA Stems

Stem 1: "A 45-year-old woman (BMI 38) with T2DM and hypertension requests bariatric surgery. Does she meet NICE criteria?"

• Answer: YES. BMI ≥35 + weight-related comorbidity (T2DM, HTN).

Stem 2: "Mechanism of action of orlistat?"

• Answer: Pancreatic and gastric lipase inhibitor (blocks ~30% dietary fat absorption).

Stem 3: "Patient on liraglutide develops severe epigastric pain radiating to back, with vomiting. Diagnosis?"

• Answer: Acute pancreatitis (rare but serious side effect of GLP-1 agonists). STOP drug immediately. Investigate (amylase/lipase, CT).

Stem 4: "Most common monogenic cause of severe childhood-onset obesity?"

• Answer: MC4R (melanocortin-4 receptor) mutations (~2-5% of severe obesity).

Stem 5: "6 months post-Roux-en-Y gastric bypass, patient has macrocytic anaemia. Likely deficiency?"

• Answer: Vitamin B12 (bypassed stomach → lost intrinsic factor → malabsorption). Requires lifelong B12 supplementation.

Stem 6: "Post-gastric bypass patient develops intermittent severe colicky abdominal pain and vomiting. CT shows small bowel obstruction. Diagnosis?"

• Answer: Internal hernia (bowel herniation through mesenteric defects created during RYGB). Requires urgent surgical repair.

Stem 7: "Patient develops dizziness, sweating, palpitations 15 minutes after eating chocolate (post-RYGB). Diagnosis?"

• Answer: Early dumping syndrome (rapid gastric emptying of hyperosmolar food → vasomotor symptoms). Manage with dietary modification (avoid simple sugars, small frequent meals).

Stem 8: "Best predictor of visceral adiposity and metabolic risk?"

• Answer: Waist circumference (superior to BMI alone).

Viva Voce Scenarios

Scenario 1: Justify Bariatric Surgery Referral

• Examiner: "A 52-year-old man, BMI 42, T2DM on insulin, hypertension, OSA on CPAP. He requests bariatric surgery. How do you assess?"
• Candidate:
  • "Criteria: Meets NICE CG189 (BMI ≥40, OR ≥35 + comorbidity). He has BMI 42 alone, plus multiple comorbidities."
  • "Pre-requisites: Confirm lifestyle interventions tried (Tier 2), consider Tier 3 pharmacotherapy (though often bypassed if severe comorbidity burden). Exclude contraindications (active substance abuse, severe untreated mental illness, inability to adhere to follow-up)."
  • "Workup: Upper GI endoscopy, abdominal USS, nutritional screen (Vit D, B12, iron), psychological assessment, anaesthetic review (high-risk due to OSA)."
  • "Procedure Choice: Discuss RYGB vs sleeve. RYGB higher T2DM remission (75-80% vs 60-70%) but higher complication/nutritional deficiency risk. Patient preference important."
  • "Consent: Operative risks (leak 1-3%, VTE, bleeding), long-term risks (nutritional deficiencies requiring lifelong supplementation, dumping, marginal ulcer, 20-30% weight regain). Benefits: 60-80% T2DM remission, probable insulin cessation, OSA improvement/resolution, 29% long-term mortality reduction (SOS)."
  • "Follow-up: Lifelong. Initially frequent (2 wks, 6 wks, 3/6/12 months), then annual. Monitor weight, nutrition (FBC, B12, folate, iron, calcium, Vit D, PTH), comorbidities."

Scenario 2: Manage Post-Bariatric Complication

• Examiner: "Post-op day 5 after sleeve gastrectomy. Patient has tachycardia (HR 120), fever 38.2°C, abdominal pain. Your approach?"
• Candidate:
  • "Differential: Anastomotic/staple-line leak (MOST IMPORTANT), bleeding, abscess, VTE (PE), aspiration pneumonia."
  • "Urgency: Leak is surgical emergency. High index of suspicion."
  • "Assessment: Tachycardia often earliest sign (pain may be mild initially). Examine: peritonism? respiratory signs (pleural effusion if leak)? Observations: tachycardia, fever, hypoxia?"
  • "Investigations:"
    • Bloods: FBC (↑WCC), CRP (↑↑), lactate (↑ if septic), G&S/crossmatch.
    • Imaging: CT abdomen/pelvis with oral contrast (gold standard for leak detection). Look for free fluid, extraluminal contrast, free air, abscess.
  • "Management:"
    • NBM, IV fluids, broad-spectrum antibiotics (if septic).
    • Urgent surgical review (same team that performed surgery). May require re-operation (washout, repair/oversew leak, drainage) vs conservative (if small, contained leak: NBM, TPN, antibiotics, percutaneous drainage).
  • "Key Point: Early leak (days 1-5) high morbidity/mortality if delayed diagnosis. Tachycardia in early post-op bariatric patient = leak until proven otherwise."

Scenario 3: GLP-1 Agonist Counselling

• Examiner: "A 50-year-old woman, BMI 34, prediabetes (HbA1c 44 mmol/mol), asks about 'Wegovy injections'. How do you counsel?"
• Candidate:
  • "Eligibility: Semaglutide 2.4mg (Wegovy). NICE TA875: BMI ≥35, OR BMI 30-34.9 + comorbidity + functional impairment. She has BMI 34 + prediabetes (comorbidity). Check if functional impairment (reduced mobility, psychological distress). May meet criteria (borderline—specialist decision)."
  • Mechanism: GLP-1 receptor agonist. Acts on brain to increase fullness, reduce appetite. Delays stomach emptying. Turns down "food noise."
  • "Efficacy: STEP 1 trial: average 15% weight loss at 68 weeks (~15 kg if she weighs 100 kg). 50% of people lose ≥15%. Much more effective than lifestyle alone (which averages 3-5% loss)."
  • "Administration: Weekly subcutaneous injection (self-administered, pen device). Start low dose (0.25mg), increase monthly over 4 months to target 2.4mg (gradual titration reduces nausea)."
  • "Side Effects:"
    • Common: Nausea, vomiting, diarrhoea (usually first 4-8 weeks, then improve). Can be reduced by slow titration, eating smaller meals.
    • Serious (rare): Pancreatitis (severe abdominal pain radiating to back → STOP drug, seek medical help). Gallstones (rapid weight loss). Hypoglycaemia (very rare unless taking other diabetes drugs).
  • "Contraindications: Ask about personal/family history of thyroid cancer (medullary thyroid cancer, MEN2—absolute contraindication). Pregnancy/breastfeeding (STOP if planning pregnancy)."
  • "Duration: Chronic disease needs chronic treatment. If stopped, most weight returns within 1 year (STEP 1 extension: 67% regain). NICE allows max 2 years, then reassess (cost constraint, not clinical rationale). Ideally ongoing."
  • "Lifestyle: NOT a magic bullet. Still need healthy eating, physical activity (drug + lifestyle most effective)."
  • "Monitoring: Review 3-6 months. Continue if ≥5% weight loss. Stop if inadequate response. Monitor HbA1c (prediabetes may improve/reverse), BP, lipids."
  • "Cost/Access: Expensive (~£200/month). NHS funding limited (specialist initiation, restricted criteria). May need private prescription."

Model Viva Answers

Q: What is the mechanism of weight loss after sleeve gastrectomy? A: Multifactorial, beyond simple gastric restriction:

1. Restrictive: Reduced stomach volume (~80-100ml tubular sleeve) → early satiety, smaller portion sizes.
2. Hormonal: Removal of gastric fundus (site of ghrelin production) → ↓ghrelin (hunger hormone) → reduced appetite.
3. Incretin Effects: Rapid nutrient delivery to distal ileum → ↑GLP-1 and PYY secretion (satiety hormones).
4. Bile Acid Metabolism: Altered enterohepatic circulation → FXR/TGR5 signaling → improved glucose metabolism.
5. Gut Microbiome: Rapid, profound shifts in microbial composition (mechanism unclear).
6. Food Preferences: Reduced preference for high-fat/high-sugar foods (mechanism unknown, possibly central).

The term "metabolic surgery" reflects these pleiotropic effects beyond mechanical restriction.

Q: How does leptin resistance develop in obesity? A: Leptin is secreted by adipocytes in proportion to fat mass. It acts on hypothalamic ObRb receptors to suppress appetite (inhibit NPY/AgRP, activate POMC/CART neurons) and increase energy expenditure. In obesity:

1. Chronic Hyperleptinemia: Persistently high leptin levels desensitise hypothalamic receptors.
2. SOCS-3 Upregulation: Suppressor of Cytokine Signaling-3 inhibits leptin receptor signaling (negative feedback).
3. ER Stress: Endoplasmic reticulum stress in hypothalamic neurons impairs leptin signaling.
4. BBB Transport: Impaired leptin transport across blood-brain barrier (saturable transporter). Result: Brain interprets obese state as "starvation" despite abundant energy stores → fails to suppress appetite → perpetuates obesity. This explains why exogenous leptin is ineffective in common obesity (unlike congenital leptin deficiency, where replacement is curative).

Q: A patient 18 months post-RYGB has lost 40 kg but now develops progressive fatigue, paraesthesia, and ataxia. Diagnosis and investigation? A: Suspect Vitamin B12 deficiency (subacute combined degeneration of the cord). RYGB bypasses stomach (site of intrinsic factor production) → B12 malabsorption.

• Investigations: FBC (macrocytic anaemia), B12 level (low), methylmalonic acid and homocysteine (elevated if deficient), folate (check for combined deficiency).
• Neurological: MRI spine (may show T2 hyperintensity in dorsal columns, though often normal early), nerve conduction studies (if peripheral neuropathy suspected).
• Treatment: Urgent IM hydroxocobalamin (1mg 3× weekly until no further improvement, then maintenance 1mg every 2-3 months lifelong). Neurological damage can be irreversible if delayed.
• Prevention: All post-RYGB patients should have lifelong B12 supplementation (IM or high-dose oral 1000mcg daily) + annual monitoring (FBC, B12, folate, iron).

Alternative considerations if atypical: Thiamine (B1) deficiency (Wernicke-Korsakoff if history of persistent vomiting—confusion, ophthalmoplegia, ataxia. Treat with urgent IV thiamine). Copper deficiency (myelopathy mimicking B12 deficiency, very rare post-RYGB). Vitamin E deficiency (ataxia, peripheral neuropathy, rare).

---

14. Key Take-Home Messages

1. Obesity is a Chronic Disease: Neurohormonal dysregulation, not moral failing. Requires lifelong management.
2. Set Point Biology: The brain defends elevated body weight through hormonal adaptations (↑ghrelin, ↓leptin, metabolic adaptation). Weight regain is predictable physiology, not personal failure.
3. 5-10% Loss is Clinically Meaningful: Do not let "perfect" be the enemy of "good." Even modest weight loss profoundly improves cardiometabolic health.
4. Tiered Approach: Lifestyle foundation (all patients) → Pharmacotherapy (BMI ≥30 or ≥27 + comorbidity) → Surgery (BMI ≥40 or ≥35 + comorbidity).
5. GLP-1 Agonists Have Revolutionised Medical Management: Semaglutide 2.4mg (~15% loss), tirzepatide (~22% loss). Require ongoing treatment (chronic disease model). Cardiovascular benefit beyond weight loss (SELECT trial).
6. Bariatric Surgery is Most Effective Long-Term: 20-35% total body weight loss, 60-80% T2DM remission, 29% mortality reduction (SOS study). Requires lifelong nutritional supplementation and follow-up.
7. Multidisciplinary Care: Dietitian, psychologist, physician, surgeon—coordinated approach essential.
8. Address Weight Stigma: Compassionate, non-judgmental care improves engagement and outcomes.
9. Screen for Complications: T2DM, hypertension, dyslipidaemia, OSA, NAFLD, depression. Treat comorbidities aggressively.
10. Secondary Causes are Rare (less than 10%): Always screen (TSH, consider Cushing's if features, medication review) but do not delay evidence-based management.

---

15. References

Primary Sources

1. World Health Organization. Obesity and Overweight Factsheet. WHO, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Rubino F, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497. DOI: 10.1038/s41591-020-0803-x

3. National Institute for Health and Care Excellence (NICE). Obesity: identification, assessment and management. Clinical guideline [CG189]. NICE, 2014 (updated 2022). https://www.nice.org.uk/guidance/cg189

4. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-266. DOI: 10.1056/NEJMra1514009

5. Wilding JPH, et al. (STEP 1 Investigators). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183

6. Jastreboff AM, et al. (SURMOUNT-1 Investigators). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

7. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. N Engl J Med. 2017;376(7):641-651. DOI: 10.1056/NEJMoa1600869

8. Schwartz MW, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017;38(4):267-296. DOI: 10.1210/er.2017-00111

9. Sjöström L, et al. (Swedish Obese Subjects Study). Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-2304. DOI: 10.1001/jama.2014.5988

10. Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61(2):257-264. DOI: 10.1007/s00125-017-4513-y

11. Knowler WC, et al. (Diabetes Prevention Program Research Group). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. DOI: 10.1056/NEJMoa012512

12. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. DOI: 10.1016/S0140-6736(17)32129-3

13. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776-786. DOI: 10.1016/S0140-6736(16)30175-1

14. Morton GJ, et al. Central nervous system control of food intake and body weight. Nature. 2006;443(7109):289-295. DOI: 10.1038/nature05026

15. Cummings DE, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623-1630. DOI: 10.1056/NEJMoa012908

16. Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009;117(6):241-250. DOI: 10.1055/s-0029-1192044

17. Ley RE, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023. DOI: 10.1038/4441022a

18. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206. DOI: 10.1038/nature14177

19. Domecq JP, et al. Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-370. DOI: 10.1210/jc.2014-3421

20. Lean MEJ, et al. (DiRECT trial investigators). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-551. DOI: 10.1016/S0140-6736(17)33102-1

21. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring). 2016;24(8):1612-1619. DOI: 10.1002/oby.21538

22. Lauby-Secretan B, et al. (IARC Working Group). Body Fatness and Cancer—Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. DOI: 10.1056/NEJMsr1606602

23. Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local guidelines, and specialist consultation where appropriate. Always refer to current evidence-based guidelines and seek senior/specialist input for complex cases.